India Globalization Surges On CBD Trial For Alzheimer’s

India Globalization Capital, Inc. (NYSE: IGC) shares are advancing strongly after the company unveiled plans to start an early-stage clinical trial for its cannabinoid, or CBD, formulation.

What Happened: Maryland-based Indian Globalization Fund, which operates two business lines, namely infrastructure and life sciences, said late Tuesday the FDA had notified July 30 that it could go ahead with a Phase 1 trial to evaluate its investigational CBD formulation for the treatment of patients suffering from mild-to-severe dementia due to Alzheimer’s disease.

The company said it plans to begin …

Full story available on

More India Globalization Surges On CBD Trial For Alzheimer's